BD Unveils CFO Transition and Revenue Insights
BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent global medical technology firm, publicly shared a transition plan which involves Chris DelOrefice stepping down from his role as the executive vice president and chief financial officer (CFO) on December 5, 2025. DelOrefice is departing to seek new professional opportunities, marking a significant change in leadership.
In the interim, Vitor Roque, the company's senior vice president overseeing finance, business units, and corporate financial planning and analysis, has been appointed as the interim CFO. Roque assumes this role immediately upon DelOrefice’s departure, working closely with DelOrefice and BD's leadership to ensure a seamless transition and continuity in financial strategy.
"Chris has been an integral member of our Executive Leadership Team for four years, driving the BD 2025 strategy and spearheading a transformation within our portfolio to navigate the ever-changing healthcare landscape successfully," remarked Tom Polen, BD's CEO and chairman.
Polen also provided praise for Roque, highlighting his extensive experience of two decades that spans various finance leadership roles within BD. His familiarity with the company’s financial landscape equips him well for the interim CFO position as BD continues to progress toward its strategic financial objectives.
Preliminary Revenue Results for Fiscal Year 2025
In conjunction with the leadership announcement, BD discussed preliminary financial results for the fourth quarter and full year of fiscal 2025 concluding on September 30, 2025. Reports indicate:
- The fourth quarter unveiled preliminary unaudited revenues approximating $5.9 billion. This reflects an estimated year-on-year increase of around 8.3% on a reported basis, 7.0% when adjusting for currency fluctuations, and 3.9% on an organic basis.
- For the entire fiscal year, preliminary unaudited revenues reached about $21.8 billion. This denotes an estimated increase of approximately 8.2% on a reported basis, 7.7% when adjusting for currency, and 2.9% on an organic basis.
Polen continued by acknowledging the ongoing challenges in the macroeconomic environment, specifically mentioning the pressures that affected certain sectors such as the Pharmaceutical Systems vaccines and Biosciences research segments. However, BD sustained impressive growth across several areas like the BD Interventional segment, Advanced Patient Monitoring, and Medication Delivery Solutions.
Looking forward, BD will remain committed to executing its strategic plans while actively seeking opportunities to drive growth and maintain momentum regarding profit margins. Upcoming insights about BD's revised strategy for fiscal 2026 will be shared during the next earnings call.
Fiscal Year 2025 Earnings Guidance
Looking ahead, BD anticipates delivering its adjusted diluted earnings per share (EPS) for fiscal year 2025, at or above the previously stated guidance midpoint. This EPS reflects various assumptions that management has reviewed, and while forecasts exclude numerous potential costs that may arise during the fiscal year, the adjustments offer a clearer view of BD's expected underlying financial performance for the year ahead.
Invitations for Upcoming Conference Call
As previously announced, BD plans to host an audio webcast detailing financial results for the fourth quarter and full year fiscal 2025 on November 6, 2025. The meeting can be followed via BD's investor relations channels, where accompanying materials will be distributed to provide further insight into their quarterly financial performance.
Non-GAAP Financial Metrics Explained
This report also contains non-GAAP financial measures pertaining to preliminary revenue growth rates based on adjusted and organic strategies. BD management considers these measures to better analyze operational performance and assess trends that influence their financial outcomes.
As further discussions unfold, BD remains transparent about how these financial metrics assist in understanding its operations' performance and future expectations.
About BD
BD stands out as one of the largest global medical technology enterprises dedicated to enhancing health through advancements in medical discovery, diagnostics, and care delivery. The company develops innovative technology, solutions, and services that help healthcare professionals and researchers improve patient therapy delivery and clinical processes.
With a workforce exceeding 70,000 employees, BD is passionate about enhancing the safety and efficacy of care provided by clinicians. Operating in almost every country, BD collaborates with various organizations worldwide, striving to tackle global health challenges, improve healthcare access, and enhance outcomes for better health around the globe. For additional information, BD is active across platforms like LinkedIn and X (formerly Twitter).
Frequently Asked Questions
What is the reason for the CFO transition at BD?
The CFO, Chris DelOrefice, is leaving to pursue a new professional opportunity, prompting the company to appoint Vitor Roque as the interim CFO.
What was BD's financial performance for fiscal year 2025?
BD reported preliminary unaudited revenues of approximately $21.8 billion for the fiscal year, marking an estimated growth of 8.2% from the previous year.
When will BD's next earnings call take place?
The next earnings conference call is scheduled for November 6, 2025, where they will disclose further financial results and strategic updates.
What role does Vitor Roque hold in BD?
Vitor Roque has been named interim CFO and has extensive experience in finance leadership within the company, having served in various roles for two decades.
How does BD define organic revenue growth?
Organic revenue growth refers to revenues adjusted for acquisitions and divestitures, focusing solely on the company’s operational performance without external influences.
